Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

allo-hMSCs

Cell therapy · developed by Longeveron

Phase 1/2 Most advanced trial (none active)
LGVN Developer
2 Registered trials

What is allo-hMSCs?

allo-hMSCs are allogeneic human mesenchymal stem cells, cell-based agents studied in frailty and hypoplastic left heart syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Cardiovascular, Musculoskeletal
Developer
Longeveron Inc. (LGVN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02065245 Phase 1/2 Frailty Completed LGVN
NCT02398604 Phase 1 Hypoplastic Left Heart Syndrome Terminated LGVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

FrailtyHypoplastic Left Heart Syndrome

More from Longeveron

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGVN page.

Follow LGVN, the company behind allo-hMSCs

See LGVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGVN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.